Akèy › Dematomiyozit
Etid klinik pou Dematomiyozit ap rekrite nan Etazini
26 etid pou Dematomiyozit ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Durham, NC8 etid
- Washington, DC7 etid
- Boston, MA5 etid
- Houston, TX5 etid
- New York City, NY5 etid
- Pittsburgh, PA5 etid
- Miami, FL4 etid
- Baltimore, MD4 etid
- Philadelphia, PA4 etid
- Phoenix, AZ3 etid
- Cleveland, OH3 etid
- Jacksonville, FL3 etid
- Kansas City, KS3 etid
- Aurora, CO3 etid
- New Haven, CT3 etid
Pa eta
- Arizona4 etid
- Colorado4 etid
- Connecticut3 etid
- Florid7 etid
- Illinois3 etid
- Kalifòni9 etid
- Kansas4 etid
- Maryland9 etid
- Massachusetts5 etid
- New York6 etid
- North Carolina8 etid
- Ohio5 etid
- Pennsylvania7 etid
- Texas6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Ap rekriteFaz 2
Laj 18 a 60 · Tout sèks · Mizajou Sep 30, 2026 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01276470Natural History of Inflammatory Muscle Diseases
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 120 · Tout sèks · Mizajou Sep 24, 2026 · NCT05738824Adult and Juvenile Myositis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 24, 2026 · NCT00017914A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 24, 2026 · NCT06455449Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05895786A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104FT839 in Autoimmune Diseases
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 2, 2026 · NCT07800871Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07486869A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06698796Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT07089121Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Jul 22, 2026 · NCT06371417A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07138898Intralesional Injection of STS in Treatment of Calcinosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06672822Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 27, 2026 · NCT07160205Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 30, 2026 · NCT02945345Rheumatology Patient Registry and Biorepository
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Feb 13, 2026 · NCT04402086A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 11, 2026 · NCT07403188MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Ap rekriteEtid obsèvasyon
Laj 7 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT07374107Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Ap rekriteFaz 2
Laj 18 a 89 · Tout sèks · Mizajou Oct 8, 2025 · NCT06857240Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Ap rekriteFaz 1
Laj 25 a 72 · Tout sèks · Mizajou May 21, 2025 · NCT06298019Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.